Paul R. Edick - 13 Dec 2022 Form 4 Insider Report for Xeris Biopharma Holdings, Inc. (XERS)

Role
Chairman & Chief Executive Officer, Director
Signature
/s/ Beth Hecht as Attorney-in-Fact
Issuer symbol
XERS
Transactions as of
13 Dec 2022
Net transactions value
+$29,000
Form type
4
Filing time
14 Dec 2022, 15:11:11 UTC
Previous filing
13 May 2022
Next filing
01 Feb 2023
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction XERS Common Stock Purchase $29,000 +20,000 +1.3% $1.45 1,528,064 13 Dec 2022 Direct
holding XERS Common Stock 33,430 13 Dec 2022 By: Paul R. Edick 2008 Revocable Trust u/d/t dated 6/25/2018 F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The reporting person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.

Remarks:

Chairman & Chief Executive Officer